


## SARS-CoV-2 nsp13-IN-1

Cat. No.:	HY-150622
CAS No.:	1005304-44-8
Molecular Formula:	C <sub>27</sub> H <sub>20</sub> N <sub>4</sub> O <sub>2</sub>
Molecular Weight:	432.47
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 41.67 mg/mL (96.35 mM); ultrasonic and warming and heat to 60°C				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.3123 mL	11.5615 mL	23.1230 mL
		5 mM	0.4625 mL	2.3123 mL	4.6246 mL
		10 mM	0.2312 mL	1.1561 mL	2.3123 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (4.81 mM); Suspended solution; Need ultrasonic				

### BIOLOGICAL ACTIVITY

Description	SARS-CoV-2 nsp13-IN-1 (compound C1) is a potent nsp13 (non-structural protein 13) inhibitor. SARS-CoV-2 nsp13-IN-1 only inhibits nsp13 ssDNA <sup>+</sup> ATPase, with an IC <sub>50</sub> of 6 μM. SARS-CoV-2 nsp13-IN-1 does not inhibit ssDNA <sup>-</sup> ATPase. SARS-CoV-2 nsp13-IN-1 can be used for COVID-19 research <sup>[1]</sup> .
IC <sub>50</sub> & Target	IC <sub>50</sub> : 6 ± 0.5 μM (nsp13 ssDNA <sup>+</sup> ATPase) <sup>[1]</sup>

### REFERENCES

[1]. Yazdi AK, et al. Kinetic Characterization of SARS-CoV-2 nsp13 ATPase Activity and Discovery of Small-Molecule Inhibitors. ACS Infect Dis. 2022 Jul 13.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA